Showing results (581-590 of 652) with videos related to

Sort By:
Pageof 66
Neuropsychopharmacology Reports|October 28, 2023
Association of worker's mental health with changes in exercise time, going-out time, and screen time (TV time, internet time, and game time) before and after the COVID-19 pandemic: A cross-sectional studyYutaro Okawa, Shinichi Iwasaki, Yasuhiko Deguchi, et al.
Neuropsychopharmacology Reports|September 22, 2023
Characteristics of patients with anxiety disorder without selective serotonin reuptake inhibitor prescription over a two-year period of pharmacotherapyKeisuke Mori, Fumitoshi Kodaka, Arisa Yamamoto, et al.
Neuropsychopharmacology Reports|July 19, 2023
At-risk internet addiction and related factors among senior high school teachers in Japan based on a Nationwide surveyMari Fukuda, Mohammad Chowdhury, Tanvir Turin Chowdhury, et al.
Neuropsychopharmacology Reports|July 15, 2023
Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophreniaYumi Aoki, Yoshikazu Takaesu, Kentaro Matsui, et al.
Neuropsychopharmacology Reports|June 16, 2023
Systemic administration of the antisense oligonucleotide NS-089/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trialTakami Ishizuka, Hirofumi Komaki, Yasuko Asahina, et al.
Neuropsychopharmacology Reports|February 6, 2019
Repeated methamphetamine treatment increases spine density in the nucleus accumbens of serotonin transporter knockout miceYoshiyuki Kasahara, Yasufumi Sakakibara, Takashi Hiratsuka, et al.
Neuropsychopharmacology Reports|September 29, 2020
Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorderMasaaki Iwata, Koichi Kaneko
Neuropsychopharmacology Reports|September 8, 2020
Risk factors for the onset of dependence and chronic psychosis due to cannabis use: Survey of patients with cannabis-related psychiatric disordersToshihiko Matsumoto, Toshitaka Kawabata, Kyoji Okita, et al.
Neuropsychopharmacology Reports|September 9, 2020
Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in JapanTaro Kishi, Reiji Yoshimura, Kenji Sakuma, et al.
Neuropsychopharmacology Reports|March 18, 2020
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophreniaKamiyu Ogyu, Yoshihiro Noda, Kazunari Yoshida, et al.
Pageof 66